Reply To: New BRAF/MEK inhibitors coming to market

[Mandi Murph]

Well said ladies, I certainly echo your points on the clinical decsision making. It is going to be great to have another option to enable continuation of therapy. Somtimes this can be confusing for patients, in justifying a switch of therapy, I usually use the analogy of changing blood pressure medications such as a betablocker, within the same category, that usually helps as that analaogy tends to be relatable.

Additionally, I think the role of pt support programs can play a role of initial choice of therapy.